Keywords: daclizumab, impresses, ms, therapy, biotechnology, firms, biogen

Daclizumab impresses as MS therapy

Article | 22 October 2007

Print This

US biotechnology firms Biogen Idec and PDL BioPharma say that Phase II data shows that adding daclizumab to interferon beta ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in